Drug Type Bispecific antibody |
Synonyms MP-3546 |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), LGALS3BP inhibitors(galectin 3 binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | IT | - |